Richmond Mutual Bancorp Bolsa (NASDAQ: RMBI)

Últimas noticias sobre Richmond Mutual Bancorp (NASDAQ:RMBI) Bolsa

Richmond Mutual Bancorp

Richmond Mutual Bancorp Inc is a United States-based banking company. Its principal business consists of attracting deposits from the general public & brokered deposits and investing those funds predominantly in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one-to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. The company has one reportable segment which is Community Banking.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ALUR

ASST

AVBP

CNOB

DWTX

HSTM

IPHA

LGTY

MDXG

The Marygold Companies, Inc. Common Stock

MGLD

MULN

ONCO

PXLW

RMBI

TVGN

VINC

Explora los movimientos más destacados del pre-mercado, incluyendo el aumento del 23% en Logility y más sorpresas.

Acciones de Logility Supply Chain (LGTY) suben un 23%; 20 acciones que se mueven en el premercado de EE.UU.

Richmond Mutual Bancorporation, Inc. - Common Stock

Richmond Mutual Bancorp Inc

Citigroup analyst Alexander Hacking maintains Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) with a Neutral and raises the price target from $7.5 to $11.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Cleveland-Cliffs, Raises Price Target to $11

Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) has outperformed the market over the past 20 years by 3.45% on an annualized basis producing an average annual return of 11.88%. Currently, Micron Technology has a market capitalization of $126.57 billion. 
Buying $1000 In MU: If an investor had bought $1000 of MU stock 20 years ago, it would be worth $9,507.14 today based on a price of $113.10 for MU at the time of writing.
<h3>Micron Technology's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753136112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Micron Technology Stock In The Last 20 Years

Global-leading broadband fibre and wireless infrastructure will connect more homes and businesses to faster internet speeds, new and exciting services and improved affordability
This investment programme comes on top of the $70 billion TELUS announced earlier this year to enhance broadband connectivity, strengthen competition and consumer choice, support Canadian AI leadership and fuel economic growth through 2029. This builds on the more than $276 billion TELUS has committed since 2000
VANCOUVER, BC, July 21, 2025 /CNW/ - TELUS is excited to announce a $2-billion investment to deliver our global-leading broadband services across Ontario and Quebec over the next five years. This investment comes as a result of the CRTC confirmation of the wholesale fibre-to-the-premise (FTTP) framework and serves as a complement to our wholesale fibre access agreements, allowing TELUS to deliver national scale, accelerate network builds and drive investment, competition and affordability in Canada. This marks a significant milestone in TELUS' ongoing efforts to bring Canada's fastest and most reliable broadband services to more communities – fueling economic growth and ensuring all Canadians have access to next generation digital services.

Contracts

Global

CORRECTION: TELUS Invests $2B To Deliver Its Broadband Services Across Ontario And Quebec Over The Next 5-Years

Crypto billionaire and Tron (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/trx/usd">TRX</a>) founder Justin Sun will soon be headed to space, taking his place on an upcoming Blue Origin spaceflight after his <a href="https://www.benzinga.com/markets/cryptocurrency/21/12/24746545/tron-founder-justin-sun-paid-28m-for-blue-origin-flight-heres-how-hes-picking-5-people-to-">winning bid in 2021.</a>
What Happened: Sun is the latest big name to head to space aboard a Blue Origin spaceflight, following <a href="https://www.benzinga.com/general/space/25/02/44019974/katy-perry-gayle-king-lauren-sanchez-headline-next-blue-origin-space-flight-how-jeff-bezos-fiancee-crew-will-make-history">an all-female crew </a>earlier this year that included Jeff Bezos' then fiancée Lauren Sánchez, media personality Gayle King and singer Katy Perry.
"In 2021, I bid $28M for a seat on @BlueOrign's New Shepard rocket — funds that went to @clubforfuture, Blue Origin's foundation, to support 19 space-based charities inspiring the next generation of STEM leaders. Proud to join Blue Origin's NS-34 mission and continue encouraging youth to pursue their dreams in science and space!" Sun <a href="https://x.com/justinsuntron/status/1947308659266187675">tweeted</a>.
Blue Origin's NS-34 <a href="https://www.blueorigin.com/news/new-shepard-ns-34-mission">marks </a>its 14th human flight for the New Shepard program and 34th overall mission. The company, which was founded by Amazon.com founder Jeff Bezos, has flown 70 people above the Karman line, which is the internationally recognized space boundary.
A date for the space flight with Sun will be announced soon.
Also featured as part of the space crew are:
<ul class="wp-block-list">
<li>Arvinder (Arvi) Singh Bahal: real estate investor</li>
<li>Gökhan Erdem: Turkish businessman</li>
<li>Deborah Martorell: Puerto Rican meteorologist and journalist</li>
<li>Lionel Pitchford: Englishman who enjoys traveling the world</li>
<li>James (J.D.) Russell: serial entrepreneur, founder Alpha Funds, founder Alpha Aerospace</li>
</ul>
This marks the second Blue Origin space flight for Russell, who was also part of the crew for NS-28.
Read Also: <a href="https://www.benzinga.com/general/space/25/04/45087625/jeff-bezos-wants-to-send-you-to-space-after-katy-perry-heres-how-much-a-reservation-with-blue-origin-costs">Jeff Bezos Wants To Send You To Space After Katy Perry: Here&#8217;s How Much A Reservation With Blue Origin Costs</a>
Why It's Important: Sun was the winner of a bid for the first seat on New Shepard back in 2021, but has yet to go to space.
The $28 million in proceeds were donated to Club for the Future, which picked 19 space-related nonprofits that each received a $1 million grant.
Sun has made headlines in the crypto sector in recent months. He was <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45602645/crypto-mogul-justin-sun-dines-with-trump-then-flexes-100k-watch-whats-the-deal">invited to a dinner</a> with President Donald Trump as one of the top holders of the Trump Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TRUMP</a>) and is also an investor in World Liberty Financial, a crypto-related company with ties to the president's family.
The SEC paused an investigation into Sun and his companies for market manipulation earlier this year, which came after the investments in Trump-related cryptocurrency ventures. The SEC pause may also be what was needed to get Sun to space finally after winning his bid back in 2021.
This marks the fifth human spaceflight for Blue Origin in 2025. Among the bigger names to fly to space with Blue Origin along with pop singer Perry include Bezos himself,&nbsp;William Shatner, Michael Strahan&nbsp;and Dude Perfect&#8217;s&nbsp;Coby Cotton.
Blue Origin reservations are open to anyone 18 years or older by filling out some information, including a description of yourself in less than 500 characters.
The one missing detail in the reservation is the total price involved for an unforgettable &#8220;Window seat&#8221; to space. The reservation form says a $150,000 fully, refundable deposit is collected by Blue Origin after booking a reservation.
This means the space flight with Blue Origin is more than $150,000. Virgin Galactic Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>), which is currently in a pause of taking humans to space, has charged between $200,000 to $450,000 per person for past space flights.
Virgin Galactic is expected to begin taking people to space again in 2026 as long as it passes required tests and its plan stays on track. Previous<a href="https://www.benzinga.com/news/21/07/21945008/spacex-ceo-elon-musk-books-a-flight-with-richard-bransons-virgin-galactic" target="_blank" rel="noreferrer noopener">&nbsp;reservation holders for flights&nbsp;</a>with Virgin Galactic included&nbsp;Leonardo DiCaprio, Justin Bieber&nbsp;and&nbsp;Elon Musk.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45965595/eric-trump-says-he-doesnt-have-public-involvement-in-justin-suns-mstr-type-public-venture-but-admits-hes-a-fan-of-tron-and-its-founder">Eric Trump Says He Doesn&#8217;t Have &#8216;Public Involvement&#8217; In Justin Sun&#8217;s MSTR-Type Public Venture, But Admits He&#8217;s A &#8216;Fan&#8217; Of Tron And Its Founder&nbsp;</a></li>
</ul>
Photo courtesy of Blue Origin; New Shepard lifts off from Launch Site One during NS-27. (October 23, 2024)

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

SPACE

$TRUMP

$TRX

SPCE

Crypto Billionaire Justin Sun Set To Board Jeff Bezos' Blue Origin Spaceship After $28 Million Record Bid

Barclays analyst Richard Hightower maintains Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Overweight and lowers the price target from $37 to $36.

EPRT

Barclays Maintains Overweight on Essential Properties, Lowers Price Target to $36

Barclays analyst Richard Hightower maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Equal-Weight and raises the price target from $54 to $55.

GLPI

Barclays Maintains Equal-Weight on Gaming and Leisure Props, Raises Price Target to $55

5 analysts have expressed a variety of opinions on CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for CytoSorbents, presenting an average target of $8.2, a high estimate of $10.00, and a low estimate of $1.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1753135316_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive CytoSorbents is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Sean Lee</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$1.00</td>
<td>$1.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CytoSorbents. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CytoSorbents compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for CytoSorbents's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of CytoSorbents's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CTSO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CytoSorbents analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering CytoSorbents: A Closer Look</h2>
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
<h3>Unraveling the Financial Story of CytoSorbents</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3M period, CytoSorbents faced challenges, resulting in a decline of approximately -2.92% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: CytoSorbents's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -16.94%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): CytoSorbents's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.53% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -3.01%, the company showcases effective utilization of assets.
Debt Management: CytoSorbents's debt-to-equity ratio stands notably higher than the industry average, reaching 1.85. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTSO

A Glimpse Into The Expert Outlook On CytoSorbents Through 5 Analysts

Barclays analyst Richard Hightower downgrades NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) from Overweight to Underweight and lowers the price target from $46 to $44.

Downgrades

Barclays Downgrades NNN REIT to Underweight, Lowers Price Target to $44

WaFd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFD#NASDAQ">WAFD</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $32.25, a high estimate of $33.00, and a low estimate of $31.00. This current average has increased by 6.61% from the previous average price target of $30.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1753135285_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of WaFd by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Rulis</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andy Terrell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to WaFd. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of WaFd compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for WaFd's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of WaFd's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAFD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WaFd analyst ratings.</a>
<h2>Delving into WaFd's Background</h2>
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
<h3>WaFd: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: WaFd's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 5.23%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: WaFd's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 29.29%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): WaFd's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.93%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): WaFd's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.19%, the company may face hurdles in achieving optimal financial performance.
Debt Management: WaFd's debt-to-equity ratio surpasses industry norms, standing at 1.03. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WAFD

What 4 Analyst Ratings Have To Say About WaFd

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $149.33, along with a high estimate of $162.00 and a low estimate of $141.00. This upward trend is apparent, with the current average reflecting a 5.16% increase from the previous average price target of $142.00.
<img src="https://www.benzinga.com/files/images/story/2025/1753135266_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Xylem among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$148.00</td>
<td>-</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$141.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$146.00</td>
<td>$149.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Xylem. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Xylem compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Xylem's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Xylem's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/XYL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Xylem analyst ratings.</a>
<h2>Unveiling the Story Behind Xylem</h2>
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.
<h3>Xylem: Delving into Financials</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Xylem displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 1.77%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 8.17%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.58%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Xylem's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.02%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.2.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Xylem: What You Need To Know

Throughout the last three months, 12 analysts have evaluated Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Intel, presenting an average target of $20.71, a high estimate of $25.00, and a low estimate of $14.00. This current average has increased by 0.05% from the previous average price target of $20.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1753135258_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Intel. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ruben Roy</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$24.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Ross Seymore</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Sell</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Sell</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intel. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intel compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Intel's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Intel's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INTC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intel analyst ratings.</a>
<h2>All You Need to Know About Intel</h2>
Intel is a leading digital chipmaker, focused on the design and manufacturing of microprocessors for the global personal computer and data center markets. Intel pioneered the x86 architecture for microprocessors and was the prime proponent of Moore's law for advances in semiconductor manufacturing. Intel remains the market share leader in central processing units in both the PC and server end markets. Intel has also been expanding into new adjacencies, such as communications infrastructure, automotive, and the Internet of Things. Further, Intel expects to leverage its chip manufacturing capabilities into an outsourced foundry model where it constructs chips for others.
<h3>Unraveling the Financial Story of Intel</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Intel's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -0.45%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Intel's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -6.48%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Intel's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.83%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Intel's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.42%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.5, Intel faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTC

Intel Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

Ratings for Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $94.8, a high estimate of $105.00, and a low estimate of $79.00. Marking an increase of 2.38%, the current average surpasses the previous average price target of $92.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1753135235_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Allison Transmission. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Thein</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Sherif El-Sabbahy</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$79.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Allison Transmission. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allison Transmission compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Allison Transmission's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Allison Transmission's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALSN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Allison Transmission analyst ratings.</a>
<h2>Discovering Allison Transmission: A Closer Look</h2>
Allison Transmission is the largest manufacturer of fully automatic transmissions for commercial vehicles. The company's automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business has about 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motor homes). Allison also produces electric hybrid propulsion systems and is developing e-powertrains.
<h3>Key Indicators: Allison Transmission's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Allison Transmission faced challenges, resulting in a decline of approximately -2.92% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Allison Transmission's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 25.07%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Allison Transmission's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 11.58%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Allison Transmission's ROA stands out, surpassing industry averages. With an impressive ROA of 3.59%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Allison Transmission's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.44, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

Demystifying Allison Transmission: Insights From 5 Analyst Reviews

In the current market session, Glacier Bancorp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBCI#NYSE">GBCI</a>) share price is at $45.19, after a 1.14% drop. Over the past month, the stock spiked by 7.21%, but over the past year, it actually fell by 0.02%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1753135220_0.png" alt="Past Year Chart" />

<h3>A Look at Glacier Bancorp P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Glacier Bancorp has a better P/E ratio of 24.44 than the aggregate P/E ratio of 14.25 of the Banks industry. Ideally, one might believe that Glacier Bancorp Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1753135220_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

GBCI

Price Over Earnings Overview: Glacier Bancorp

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) has outperformed the market over the past 10 years by 3.1% on an annualized basis producing an average annual return of 14.73%. Currently, HCA Healthcare has a market capitalization of $90.53 billion. 
Buying $100 In HCA: If an investor had bought $100 of HCA stock 10 years ago, it would be worth $396.12 today based on a price of $364.55 for HCA at the time of writing.
<h3>HCA Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753135218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning HCA Healthcare Stock In The Last 10 Years

Throughout the last three months, 6 analysts have evaluated Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $19.67, a high estimate of $21.00, and a low estimate of $18.00. This upward trend is evident, with the current average reflecting a 9.28% increase from the previous average price target of $18.00.
<img src="https://www.benzinga.com/files/images/story/2025/1753135217_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Huntington Bancshares by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>David Long</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Brian Foran</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brian Foran</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$20.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Huntington Bancshares. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Huntington Bancshares compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Huntington Bancshares's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Huntington Bancshares's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HBAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Huntington Bancshares analyst ratings.</a>
<h2>Get to Know Huntington Bancshares Better</h2>
Huntington is a regional US bank with around $200 billion in assets (as of 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
<h3>Huntington Bancshares's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3M period, Huntington Bancshares showcased positive performance, achieving a revenue growth rate of 9.46% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 26.04%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Huntington Bancshares's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.76%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Huntington Bancshares's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.24%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.01, caution is advised due to increased financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HBAN

Huntington Bancshares Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

<a href="https://www.bloomberg.com/news/articles/2025-07-21/oracle-in-talks-for-100-million-skydance-paramount-cloud-deal">https://www.bloomberg.com/news/articles/2025-07-21/oracle-in-talks-for-100-million-skydance-paramount-cloud-deal</a>

General

ORCL

PARA

'Oracle in Talks for $100 Million Skydance-Paramount Cloud Deal'- Bloomberg

On Monday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/tagrisso-plus-chemotherapy-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-egfr-mutated-advanced-lung-cancer.html" rel="noreferrer noopener">study</a> demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy for patients with 1st-line locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">non-small cell lung cancer (NSCLC)</a>.​
The final OS analysis demonstrates consistent survival benefit, as reported in the interim OS results.
It builds on the previously presented primary endpoint data, demonstrating the longest-reported median progression-free survival (PFS) in this setting.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46444819/astrazenecas-therapy-for-rare-protein-deposit-condition-fails" rel="noreferrer noopener">AstraZeneca&#8217;s Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition</a>
In September 2023, AstraZeneca released data from the FLAURA2 Phase 3 trial showing Tagrisso (osimertinib) in combination with chemotherapy reduced the risk of disease progression or death by 38% compared to Tagrisso alone in patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
According to the investigator&#8217;s assessment, the combination extended median progression-free survival by 8.8 months <a target="_blank" href="https://www.benzinga.com/general/biotech/23/09/34438541/astrazenecas-reinforces-hold-in-lung-cancer-settings-touts-promising-data-from-three-trials?_gl=1&#x2A;8ut96x&#x2A;_gcl_au&#x2A;MTA0Mzg4NjY1MC4xNzUwMDYyNTg3&#x2A;_ga&#x2A;R1MyLjEuczE3NTMwODY0MjgkbzE4OSRnMSR0MTc1MzA5OTgzMSRqNjAkbDAkaDA.&#x2A;_ga_V7ZK73W7N0&#x2A;czE3NTMwODY0MjgkbzE4OSRnMSR0MTc1MzA5OTgzMSRqNjAkbDAkaDA." rel="noreferrer noopener">compared to Tagrisso alone</a>.&nbsp;
In March 2024, results from the FLAURA2 Phase 3 <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-the-addition-chemotherapy-showed-favourable-trend-overall-survival-egfr-mutated-advanced-lung-cancer-further-follow-flaura2-phase-iii-trial.html#!" rel="noreferrer noopener">trial</a> showed Tagrisso, with the addition of chemotherapy,​ provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Tagrisso, with the addition of chemotherapy, also demonstrated a favorable trend toward overall survival improvement at two years of follow-up.
With longer follow-up, the safety profile of Tagrisso plus chemotherapy continues to be manageable and consistent with the established profiles of the individual medicines.
Adverse event (AE) rates were higher in the Tagrisso plus chemotherapy arm, driven by well-characterised chemotherapy-related AEs.&nbsp;Discontinuation rates due to AEs and on-target toxicities were low in both arms of the trial.
Based on the FLAURA2 Phase 3 trial, Tagrisso plus chemotherapy is approved in over 80 countries, including the U.S., EU, China, and Japan.
Price Action: AZN stock closed lower by 0.10% at $68.72 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46514251/taiwan-semiconductor-plans-four-new-fabs-as-ai-gold-rush-continues" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Plans Four New Fabs As AI Gold Rush Continues</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Biotech

Large Cap

Health Care

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) has outperformed the market over the past 5 years by 14.32% on an annualized basis producing an average annual return of 28.72%. Currently, Ovintiv has a market capitalization of $10.13 billion. 
Buying $1000 In OVV: If an investor had bought $1000 of OVV stock 5 years ago, it would be worth $3,527.65 today based on a price of $38.91 for OVV at the time of writing.
<h3>Ovintiv's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753134313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Ovintiv 5 Years Ago Would Be Worth Today

Peapack Gladstone Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGC#NASDAQ">PGC</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.62 by 27.07 percent. This is a 7.14 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $69.741 million which missed the analyst consensus estimate of $69.775 million by 0.05 percent. This is a 23.22 percent increase over sales of $56.597 million the same period last year.

Earnings

Earnings Misses

Peapack Gladstone Finl Q2 2025 GAAP EPS $0.45 Misses $0.62 Estimate, Sales $69.741M Miss $69.775M Estimate

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&amp;D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide.
The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production.
The $50 billion investment across our R&amp;D and manufacturing footprint in the US over the next five years also includes:
<ul>
<li>Expansion of our R&amp;D facility in Gaithersburg, Maryland</li>
<li>State-of-the-art R&amp;D center in Kendall Square, Cambridge, Massachusetts</li>
<li>Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Continuous manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials</li>
<li>Our growing research and development investment in novel medicines</li>
</ul>
Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US.
Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."
Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth."
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines."

AstraZeneca To Invest $50B In The U.S. By 2030, Building On America's Global Leadership In Medicines Manufacturing And R&D; Investment Will Support AstraZeneca's Ambition To Reach $80B Revenue By 2030, With 50% Generated In The U.S

Comments

Richmond Mutual Bancorp

Noticias

Últimas noticias sobre Richmond Mutual Bancorp (NASDAQ:RMBI) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL